These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28270565)

  • 21. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.
    Menna P; Salvatorelli E; Del Principe MI; Perrone S; Pagano L; Marchesi F; Minotti G
    Chemotherapy; 2021; 66(1-2):47-52. PubMed ID: 33677444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication.
    Shimony S; Reiss Mintz H; Shvartser Beryozkin Y; Shoham A; Raanani P; Wolach O
    Acta Haematol; 2020; 143(1):65-68. PubMed ID: 31291613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
    Podoll T; Pearson PG; Evarts J; Ingallinera T; Bibikova E; Sun H; Gohdes M; Cardinal K; Sanghvi M; Slatter JG
    Drug Metab Dispos; 2019 Feb; 47(2):145-154. PubMed ID: 30442651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
    Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
    Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Midostaurin + Chemo Ups AML Survival.
    Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.
    Xu RA; Li QQ; Gao NY; Wang J; Li XY; Ye F; Ni JH; Hu GX; Qian JC
    Food Chem Toxicol; 2023 Apr; 174():113669. PubMed ID: 36805545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
    Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
    Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells.
    Huang YC; Chao DK; Clifford Chao KS; Chen YJ
    Toxicol In Vitro; 2009 Sep; 23(6):979-85. PubMed ID: 19573588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites.
    Lacy S; Hsu B; Miles D; Aftab D; Wang R; Nguyen L
    Drug Metab Dispos; 2015 Aug; 43(8):1190-207. PubMed ID: 26015560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
    Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.
    Sanga M; James J; Marini J; Gammon G; Hale C; Li J
    Xenobiotica; 2017 Oct; 47(10):856-869. PubMed ID: 27460866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
    Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and disposition of dasatinib after oral administration to humans.
    Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs.
    Takahashi RH; Ma S; Yue Q; Kim-Kang H; Yi Y; Ly J; Boggs JW; Fettes A; McClory A; Deng Y; Hop CE; Khojasteh SC; Choo EF
    Xenobiotica; 2017 Jan; 47(1):50-65. PubMed ID: 27055783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.